Entero Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Entero Therapeutics has a total shareholder equity of $70.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $85.8M and $15.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$366.79k |
Equity | US$70.05m |
Total liabilities | US$15.77m |
Total assets | US$85.82m |
Recent financial health updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31Financial Position Analysis
Short Term Liabilities: ENTO's short term assets ($83.8M) exceed its short term liabilities ($15.7M).
Long Term Liabilities: ENTO's short term assets ($83.8M) exceed its long term liabilities ($80.2K).
Debt to Equity History and Analysis
Debt Level: ENTO is debt free.
Reducing Debt: ENTO has no debt compared to 5 years ago when its debt to equity ratio was 60.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ENTO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ENTO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.7% each year